EP Patent

EP4687899A1 — Method of treatment with iloperidone

Assigned to Vanda Pharmaceuticals Inc · Expires 2026-02-11 · 0y expired

What this patent protects

Described herein is an improved method of treatment with iloperidone or an active metabolite thereof, of a patient in need of such treatment, where such patient has a history of gout or is a carrier of a genetic variant associated with iloperidone-induced increases in serum urate…

USPTO Abstract

Described herein is an improved method of treatment with iloperidone or an active metabolite thereof, of a patient in need of such treatment, where such patient has a history of gout or is a carrier of a genetic variant associated with iloperidone-induced increases in serum urate concentration. The improved method comprises monitoring a serum urate level of the patient; and in an event that the serum urate level of the patient exceeds a reference level, initiating treatment with, or increasing a dose of a urate lowering treatment.

Drugs covered by this patent

Patent Metadata

Patent number
EP4687899A1
Jurisdiction
EP
Classification
—
Expires
2026-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Vanda Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.